DAWN Q3 2025 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$40M-57.6% YoY

Gross Profit

$35M88.7% margin

Operating Income

-$24M-60.9% margin

Net Income

-$20M-49.6% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+17.4%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$514M

Total Liabilities

$63M

Stockholders' Equity

$451M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40M	$94M	-57.6%
Gross Profit	$35M	$92M	-61.7%
Operating Income	-$24M	$30M	-181.8%
Net Income	-$20M	$37M	-153.3%

Revenue Segments

Product

$39M97%

License

$1M3%